effective treatment strategies are still missing.
In addition, dilated cardiomyopathies may develop due to genetic and unknown factors. Mutations in mitochondrial genes may cause a variety of clinical symptoms in the brain, eye, and peripheral and cardiac muscle. 10 -12 In the clinical research paper entitled 'Longterm cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases' by Karim Wahbi from the Cochin Hospital in Paris, France, 13 the authors characterized the long-term cardiac prognosis of adults with mitochondrial diseases. They retrospectively included 260 consecutive patients with genetically proven mitochondrial diseases, including mitochondrial DNA (mtDNA) single large-scale deletions, the m.3243A.G mutation in MT-TL1, other mtDNA point mutations, and 36 with nuclear gene mutations. Cardiac involvement was present at baseline in around one-third of the patients over a follow-up of 7 years. A total of 10% of the patients experienced an adverse cardiac event, defined as sudden death, death due to heart failure, resuscitated cardiac arrest, third degree atrioventricular block, sinus node dysfunction, cardiac transplantation, or hospitalization for heart failure. Patients with single large-scale mtDNA deletions or m.3243A.G mutations had the highest incidence of adverse cardiac events. Independent predictors of adverse cardiac events were intraventricular conduction block with a hazard ratio of 16.9, diabetes with a hazard ratio of 7.0, premature ventricular complexes with a hazard ratio of 3.6, and left ventricular hypertrophy with a hazard ratio of 2.5. In patients with 0, 1, and ≥2 risk factors, the incidence of adverse cardiac events was 2, 15, and 42%, respectively. Thus, patients with mitochondrial diseases are at high risk of adverse cardiac events. Independent predictors are a intraventricular conduction block, diabetes, ventricular prematurity, and left ventricular hypertrophy. The manuscript is accompanied by an excellent Editorial by Sabine Pankuweit from the Philipps-University Marburg in Germany.
14 Cardiomyopathies are an important cause of heart failure, 15 with diverse causes, particularly in younger patients. 16 Some pre-clinical and a few clinical studies suggest that transplantation of autologous bone marrow mononuclear cells may improve pump function in dilated cardiomyopathies, although clinical studies have been disappointing so far. 17 In the second clinical research paper 'Multi- 21 A summary of the main massages of these novel guidelines (the 'Ten Commendements') is provided in the CardioPuluse section of this issue. 22 The editors hope that this issue will be of interest to the readers of the European Heart Journal.
